Decoy Therapeutics (DCOY) Cash & Equivalents (2017 - 2026)

Decoy Therapeutics (DCOY) has reported Cash & Equivalents for 10 consecutive years, with $7.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 334.87% year-over-year to $7.8 million; the TTM figure through Mar 2026 stood at $7.8 million (up 334.87% YoY), while the FY2025 annual figure was $10.7 million, up 339.92% from the prior year.
• Cash & Equivalents retreated to $7.8 million in Q1 2026 per DCOY's latest filing, from $10.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $24.2 million in Q1 2022 and bottomed at $794886.0 in Q2 2025.
• Historically, Cash & Equivalents has averaged $8.8 million across 5 years, with a median of $7.6 million in 2023.
• On a YoY basis, Cash & Equivalents climbed as much as 339.92% in 2025 and fell as far as 75.71% in 2025.
• Decoy Therapeutics' Cash & Equivalents stood at $12.1 million in 2022, then sank by 51.27% to $5.9 million in 2023, then plunged by 58.74% to $2.4 million in 2024, then jumped by 339.92% to $10.7 million in 2025, then slipped by 26.98% to $7.8 million in 2026.
• Business Quant data shows DCOY's Cash & Equivalents at $7.8 million in Q1 2026, $10.7 million in Q4 2025, and $4.8 million in Q3 2025.